Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167142 | 0.91 | RAB9A (0.46) | RAB9ANPC1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3510505 | 0.90 | RAB9A (0.45) | RAB9ANPC1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3507304 | 0.89 | RAB9A (0.44) | RAB9ANPC1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3507212 | 0.88 | RAB9A (0.43) | RAB9ANPC1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3346033 | 0.87 | NPC1 (0.42) | RAB9ANPC1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3510780 | 0.87 | RAB9A (0.43) | RAB9ANPC1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3509328 | 0.87 | RAB9A (0.45) | RAB9ANPC1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3510927 | 0.87 | RAB9A (0.43) | RAB9ANPC1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3508736 | 0.87 | RAB9A (0.43) | RAB9ANPC1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL3511816 | 0.87 | RAB9A (0.43) | RAB9ANPC1KDM4EHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010107384-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-09-23 | — | — | WO | disclosed |
| CN-101821238-A | Suppress the active isophthaloyl sulfonamide derivatives of beta-secretase (BETA-SECRETASE) | COMENTIS INC | 2010-09-01 | — | — | CN | disclosed |
| EP-2178837-A2 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2010042030-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | RAB9A 3199/4885NPC1 204/4885NOTUM 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.